BR0108435A - Formulação e uso de entecavir de baixa dose - Google Patents

Formulação e uso de entecavir de baixa dose

Info

Publication number
BR0108435A
BR0108435A BR0108435-6A BRPI0108435A BR0108435A BR 0108435 A BR0108435 A BR 0108435A BR PI0108435 A BRPI0108435 A BR PI0108435A BR 0108435 A BR0108435 A BR 0108435A
Authority
BR
Brazil
Prior art keywords
entecavir
low dose
formulation
treatment
low
Prior art date
Application number
BR0108435-6A
Other languages
English (en)
Inventor
Richard J Colonno
Omar L Sprockerl
Abizer Harianawala
Divyakant Desai
Micael G Fakes
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26881354&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0108435(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0108435A publication Critical patent/BR0108435A/pt
Publication of BRPI0108435B1 publication Critical patent/BRPI0108435B1/pt
Publication of BRPI0108435B8 publication Critical patent/BRPI0108435B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"FORMULAçãO E USO DE ENTECAVIR DE BAIXA DOSE" Composições contendo uma baixa dose de entecavir são administradas em uma base diária para tratar infecção e/ou coinfecções pelo vírus da hepatite B. São fornecidas formulações para administração oral de uma baixa dose de entecavir. Outras substâncias farmaceuticamente ativas podem ser incluidas na composição do entecavir, ou podem ser administradas separadamente para o tratamento de infecção pelo vírus da hepatite B ou para o tratamento de pacientes coinfectados.
BR0108435-6 2000-02-29 2001-01-26 formulação e uso de entecavir de baixa dose BRPI0108435B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18567200P 2000-02-29 2000-02-29
US22131300P 2000-07-28 2000-07-28
PCT/US2001/002630 WO2001064221A1 (en) 2000-02-29 2001-01-26 Low dose entecavir formulation and use

Publications (3)

Publication Number Publication Date
BR0108435A true BR0108435A (pt) 2004-06-15
BRPI0108435B1 BRPI0108435B1 (pt) 2019-02-05
BRPI0108435B8 BRPI0108435B8 (pt) 2021-05-25

Family

ID=26881354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108435-6 BRPI0108435B8 (pt) 2000-02-29 2001-01-26 formulação e uso de entecavir de baixa dose

Country Status (35)

Country Link
US (1) US6627224B2 (pt)
EP (2) EP1267880B2 (pt)
JP (3) JP5140222B2 (pt)
KR (1) KR100757155B1 (pt)
AR (1) AR027965A1 (pt)
AT (1) ATE312613T1 (pt)
AU (1) AU2001229775A1 (pt)
BG (1) BG65815B1 (pt)
BR (1) BRPI0108435B8 (pt)
CA (1) CA2401569C (pt)
CO (1) CO5261593A1 (pt)
CZ (1) CZ303395B6 (pt)
DE (1) DE60115870T3 (pt)
DK (1) DK1267880T4 (pt)
EA (1) EA006181B1 (pt)
EE (1) EE05442B1 (pt)
EG (1) EG24408A (pt)
ES (1) ES2253403T5 (pt)
GE (1) GEP20053504B (pt)
HK (1) HK1048771A1 (pt)
HR (1) HRP20020649A2 (pt)
HU (1) HU230698B1 (pt)
IL (1) IL150447A0 (pt)
MX (1) MXPA02008359A (pt)
MY (1) MY127422A (pt)
NO (1) NO324014B1 (pt)
NZ (1) NZ520024A (pt)
PE (1) PE20020770A1 (pt)
PL (1) PL201411B1 (pt)
RS (1) RS51561B (pt)
SI (1) SI1267880T2 (pt)
SK (1) SK288008B6 (pt)
TW (1) TWI287988B (pt)
UA (1) UA84534C2 (pt)
WO (1) WO2001064221A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51561B (sr) * 2000-02-29 2011-08-31 Bristol-Myers Squibb Co. Formulacija male doze entekavira i upotreba
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ES2397104T3 (es) 2002-12-11 2013-03-04 Bristol-Myers Squibb Company Procedimiento y productos intermedios para la síntesis de entecavir
CN105596356A (zh) * 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
PL3138566T3 (pl) 2003-11-17 2022-03-07 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii z użyciem bh4
BRPI0416691A (pt) * 2003-11-18 2007-01-30 Boehringer Ingelheim Int forma de preparação farmacêutica sólida
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
JP4756153B2 (ja) * 2004-08-27 2011-08-24 富士製薬工業株式会社 低成分含量の錠剤の製造方法
CA2580117A1 (en) * 2004-09-23 2006-03-30 Fmc Corporation Coating composition
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN102596183B (zh) * 2009-10-28 2014-09-17 麦克内尔-Ppc股份有限公司 迅速溶出/崩解的包衣组合物
WO2011076412A1 (de) 2009-12-23 2011-06-30 Ratiopharm Gmbh Orale darreichungsform umfassend entecavir
DE102009060194A1 (de) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Orale Darreichungsform umfassend Entecavir
US9168269B2 (en) 2010-02-18 2015-10-27 The Trustees Of Princeton University Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
EP2552216B1 (en) 2010-03-31 2018-01-24 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
EP2606895A4 (en) * 2010-10-12 2014-04-02 Univ Wuhan TRANSDERMAL ABSORPTION STAMP OF ANTIVIRAL DRUG AND METHOD FOR PREPARING THE SAME
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
KR101594820B1 (ko) * 2011-06-16 2016-02-17 건일제약 주식회사 엔테카비르를 함유하는 미립구 및 이의 제조방법
KR101439635B1 (ko) 2011-11-01 2014-09-11 대원제약주식회사 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법
WO2013072937A2 (en) * 2011-11-14 2013-05-23 Hetero Research Foundation Fast release solid oral compositions of entecavir
EP2644196B1 (en) * 2012-03-26 2019-09-18 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of Entecavir
EP2644197A1 (en) * 2012-03-26 2013-10-02 Sanovel Ilac Sanayi ve Ticaret A.S. Novel Pharmaceutical Compositions of Entecavir
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CN103908436B (zh) * 2012-12-29 2016-02-10 安徽贝克生物制药有限公司 一种速释型恩替卡韦组合物
KR101512895B1 (ko) 2013-08-09 2015-04-16 대화제약 주식회사 엔테카비어를 포함하는 약학적 조성물의 제조방법
CN106573003B (zh) * 2014-06-20 2022-04-01 西梯茜生命工学股份有限公司 含有恩替卡韦作为活性成分的药物制剂及其制备方法
WO2017057147A1 (ja) * 2015-09-30 2017-04-06 株式会社ダイセル 易服用性固形製剤用粒子組成物及び該粒子組成物を含む易服用性固形製剤
KR20230112817A (ko) 2022-01-21 2023-07-28 한림대학교 산학협력단 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4489026A (en) † 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
DK0929294T3 (da) * 1996-04-04 2003-09-29 Felix Specht Fremgangsmåde til fremstilling af lavt doserede fritflydende og/eller direkte komprimerbare pulversystemer
AU4090697A (en) 1996-09-03 1998-03-26 Bristol-Myers Squibb Company Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one
AU5475799A (en) * 1998-08-10 2000-03-06 Centre National De La Recherche Scientifique Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB9820417D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820416D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
RS51561B (sr) * 2000-02-29 2011-08-31 Bristol-Myers Squibb Co. Formulacija male doze entekavira i upotreba

Also Published As

Publication number Publication date
CA2401569C (en) 2009-08-18
BG65815B1 (bg) 2010-01-29
US6627224B2 (en) 2003-09-30
EE200200484A (et) 2004-04-15
EG24408A (en) 2009-05-20
JP5140222B2 (ja) 2013-02-06
CZ303395B6 (cs) 2012-08-29
NO324014B1 (no) 2007-07-30
SK11652002A3 (sk) 2003-09-11
IL150447A0 (en) 2002-12-01
AU2001229775A1 (en) 2001-09-12
BRPI0108435B1 (pt) 2019-02-05
PL366102A1 (en) 2005-01-24
DK1267880T4 (da) 2010-05-17
BRPI0108435B8 (pt) 2021-05-25
RS51561B (sr) 2011-08-31
NO20024099L (no) 2002-08-28
DK1267880T3 (da) 2006-03-06
GEP20053504B (en) 2005-05-10
EP1642582A1 (en) 2006-04-05
EP1267880B1 (en) 2005-12-14
US20010033864A1 (en) 2001-10-25
DE60115870T2 (de) 2006-08-17
HUP0500558A3 (en) 2012-08-28
JP5921746B2 (ja) 2016-05-24
EP1267880A1 (en) 2003-01-02
JP2004503467A (ja) 2004-02-05
UA84534C2 (uk) 2008-11-10
WO2001064221A1 (en) 2001-09-07
EA200200812A1 (ru) 2003-12-25
HRP20020649A2 (en) 2004-12-31
ES2253403T5 (es) 2010-04-22
TWI287988B (en) 2007-10-11
MY127422A (en) 2006-11-30
HUP0500558A2 (hu) 2005-09-28
NO20024099D0 (no) 2002-08-28
SI1267880T1 (sl) 2006-06-30
HK1048771A1 (zh) 2003-04-17
CO5261593A1 (es) 2003-03-31
PL201411B1 (pl) 2009-04-30
HU230698B1 (hu) 2017-09-28
PE20020770A1 (es) 2002-09-06
EE05442B1 (et) 2011-08-15
YU63002A (sh) 2005-03-15
JP2015178523A (ja) 2015-10-08
BG106905A (bg) 2003-04-30
MXPA02008359A (es) 2003-02-12
KR100757155B1 (ko) 2007-09-07
SK288008B6 (sk) 2012-10-02
EP1267880B2 (en) 2010-01-20
SI1267880T2 (sl) 2010-04-30
CA2401569A1 (en) 2001-09-07
DE60115870T3 (de) 2010-07-29
NZ520024A (en) 2005-03-24
JP2012255017A (ja) 2012-12-27
DE60115870D1 (de) 2006-01-19
AR027965A1 (es) 2003-04-16
EA006181B1 (ru) 2005-10-27
ATE312613T1 (de) 2005-12-15
ES2253403T3 (es) 2006-06-01
KR20020082230A (ko) 2002-10-30

Similar Documents

Publication Publication Date Title
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
BR0107869A (pt) Composições farmacêuticas eletrogiradas
GEP20053473B (en) High Potency Dihydroergotamine Compositions
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
HRP20020088B1 (en) Levodopa/carbidopa/entacapone pharmaceutical preparation
BR9907866A (pt) Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
NO20030897D0 (no) Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
DE60019334D1 (de) Antivirale arznei
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
EP1023901A4 (en) MEDICINES FOR HEPATITIS C AND THE USE THEREOF
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
SE0001916D0 (sv) Novel formulation

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O ,11,13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH)

Free format text: TRANSFERIDO DE: BRISTOL-MYERS SQUIBB COMPANY

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B25D Requested change of name of applicant approved

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED CO

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/01/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 26/01/2021